NasdaqGM:IRONBiotechs
Will Insider 10b5-1 Sales and New ASCO Data Shift Disc Medicine's (IRON) Narrative?
Disc Medicine recently reported that its Chief Medical Officer, William Jacob Savage, sold 5,731 shares under a pre-arranged 10b5-1 trading plan while its lead program, bitopertin, continues in the Phase 3 APOLLO study with topline data expected later this year.
Separately, the company said it will present new Phase 2 RALLY-MF trial data for DISC-0974 in anemia of myelofibrosis at the upcoming ASCO Annual Meeting, building on earlier results that showed unusually strong anemia response rates...